Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
$7.04
-7.5%
$2.27
$0.66
$17.75
$45.96M0.3821.61 million shs11.35 million shs
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.21
+0.9%
$2.27
$0.95
$2.85
$19.66M0.13145,691 shs65,143 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$12.70
-0.3%
$12.83
$10.15
$15.85
$20.40M1.192,030 shs3,026 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.70
$0.73
$0.65
$7.50
$5.23M0.2693,639 shs36,617 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
-7.49%+134.67%+699.73%+496.61%+281.16%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
+0.91%-6.75%-4.74%+3.76%-11.60%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-0.31%+2.05%+1.60%-4.22%+18.47%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.00%+3.04%+0.29%-26.50%-84.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.5098 of 5 stars
0.02.00.00.03.01.70.0
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
3.7804 of 5 stars
3.52.00.03.43.10.00.6
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
1.401 of 5 stars
0.05.00.00.03.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.00
N/AN/AN/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
3.00
Buy$10.00352.49% Upside
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KTTA, ATNF, AYTU, and FNCH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
7/29/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
7/12/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
7/1/2025
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
6/30/2025
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
6/27/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/11/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/24/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/A$0.89 per shareN/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$81M0.25N/AN/A$4.64 per share0.48
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/A$10.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
-$6.17M-$15.07N/AN/AN/A-141.25%-80.77%N/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$15.84M-$0.72N/AN/A2.37%3.51%0.91%9/25/2025 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$13.90M-$10.60N/AN/AN/A-88.58%-81.79%N/A

Latest KTTA, ATNF, AYTU, and FNCH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A-$0.66N/A-$0.66N/AN/A
7/23/2025Q2 2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A-$0.30N/A-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/AN/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A
0.58
0.58
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.27
1.03
0.87
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A
3.84
3.84

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
4.07%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
33.49%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
23.92%

Insider Ownership

CompanyInsider Ownership
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
38.20%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
3.60%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
76.04 million3.73 millionNo Data
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
1608.98 million8.65 millionNot Optionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
37.44 million7.24 millionNot Optionable

Recent News About These Companies

KTTA Pasithea Therapeutics Corp. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNF

$7.04 -0.57 (-7.49%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$7.27 +0.23 (+3.27%)
As of 08/15/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Aytu BioPharma stock logo

Aytu BioPharma NASDAQ:AYTU

$2.21 +0.02 (+0.91%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$2.22 +0.01 (+0.45%)
As of 08/15/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$12.70 -0.04 (-0.31%)
As of 08/15/2025 12:40 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Pasithea Therapeutics stock logo

Pasithea Therapeutics NASDAQ:KTTA

$0.70 0.00 (0.00%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$0.71 +0.00 (+0.47%)
As of 08/15/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.